GlassScriptPhysician profile
Kishore Sunkara
NPI 1801841762
$7,704.05
in general payments reported to CMS, 2019-2025
28 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 91% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.67 · 2020: $110 · 2021: $1,035 · 2022: $2,108 · 2023: $1,645 · 2024: $1,254 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,424.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $994.20 | 2021-2025 | Vraylar |
| Corium, LLC | $900.50 | 2022-2025 | Azstarys |
| Validus Pharmaceuticals LLC | $871.35 | 2021-2025 | Equetro, Equetro, Raldesy |
| Neuronetics, INC. | $706.67 | 2021 | |
| Supernus Pharmaceuticals, INC. | $584.43 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $570.73 | 2020-2025 | Invega Sustenna, Spravato |
| Tris Pharma INC | $446.59 | 2020-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $439.80 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $320.83 | 2020-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $285.09 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $275.59 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $232.05 | 2022-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $216.62 | 2019-2022 | |
| Axsome Therapeutics, INC. | $129.15 | 2023-2025 | Auvelity |
| Noven Therapeutics, LLC | $111.84 | 2023-2025 | Xelstrym, Secuado |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $108.36 | 2022-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $85.26 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $76.48 | 2024-2025 | Relexxii |
| Novo Nordisk INC | $59.08 | 2025 | Wegovy |
| Brainsway USA INC | $56.88 | 2024 | Brainsway Deep Tms System |
| Adlon Therapeutics L.P. | $54.94 | 2019-2021 | |
| Eisai INC. | $40.17 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $28.03 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $27.94 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.69 | 2024 | Quviviq |
| Neos Therapeutics, LP | $22.23 | 2022 | |
| Biogen, INC. | $20.68 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $15.87 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishore Sunkara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.